Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2024. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of February 29, 2024, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification regarding share capital structure rather than a financial performance report.
Share Capital and Voting Rights
- Issued Share Capital: 4,314,004,593 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 196,971,155 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,117,033,438.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document focuses on the static share count as of the reporting date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,117,033,438) against internal records to determine if disclosure thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (196,971,155) to calculate the net outstanding share count accurately.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for financial metrics.